Title Formulation type Drug Evaluation Refs. Current formulation and evaluation of a Q10-loaded SLN cream: in vitro and in vivo studies SLNs–loaded cream CoQ10 Particle size analysis and zeta potential measurement of SLNswere w detected by using photon correlation spectroscopy (107) Drug–excipient compatibility was determined by differential scanning calorimetry Visualization of the colloidal dispersion was performed by TEM In vitro release study was conducted by using an automated, temperature-controlled continuous fl ow diffusion cells. In vivo antiaging capabilities of developed formulation were evaluated in 25 female volunteers by assessment of skin hydration and viscoelasticity The advantages of a CoQ10 delivery system in skin photo- protection NLCs CoQ10 Particle size and shape of NLCs were determined via Zetasizer and TEM, respectively (108) Cell viability testing was detected by using Human embryo skin fi broblasts via MTT assa Antioxidant assessment through lipid peroxidation products and intracellular ROS assays was performed by using the photometrical method Biochemical evaluation of the antioxidant parameters and enzymes activity Cell apoptosis was determined by fl uorescence microscopy In vivo skin permeation was conducted by using female Sprague– Dawley rats via fl uorescent microscopy TRF attenuates UV-induced infl ammaging: A bench to bedside study Nanoemulsion TRF In vitro studies: (52) Determination of cell viability in HaCatcell x line using MTT assay Quantifi cation of certain oxidative and infl ammatory markers in HaCat cell line after UVB exposure using the ELISA technique. ROS measurement by fl ow cytometry and fl uorescence plate reader Ex vivo studies to investigate the drug permeability and a antioxidant effect were conducted by the skin antioxidative potential method and radical sun protection factor test using skin samples from the external lobe of a fresh pig ear Clinical studies on healthy human volunteers involving UV irradiation and skin color measurements were carried out Supplementary table I Continued JOURNAL OF COSMETIC SCIENCE 348

Title Formulation type Drug Evaluation Refs. Anti-infl ammaging and antiglycation activity of a botanical ingredient from African biodiversity (Centevita™) Conventional (solution) Extract from Madagascar, and Centella asiatica Biological activity on human skin explants through determination of several parameters: (142) Thymine photodimerization induced by UV Interleukin (IL)1-α, ROS scavenging properties Antiglycation activity Antiwrinkle effect was evaluated via a clinical trial on healthy volunteers and skin parameters such as skin replicas, fi rmness, elasticity and collagen density Topical vesicular formulations of Curcuma longa extract on recuperating the ultraviolet radiation–damaged skin Liposomes, ethosomes, and transfersomes in cream Curcuma longa extract Physicochemical characterizations of the vesicular systems including particle size analysis, TEM imaging, and entrapment effi ciency determination were conducted (103) Physicochemical evaluations of creams pH, viscosity, stickiness, smoothness, stability, spreadability and microbial count were carried out Clinical study on human volunteers was performed and skin hydration and sebum content were determined Functional response of bioprotective poloxamer-structured vesicles on infl amed skin Nanovesicles (liposomes and glycerosomes modifi ed by poloxamers) Resveratrol and gallic acid Vesicles size and shape were evaluated via photon correlation spectroscopy, and cryogenic transmission electron, respectively. (93) Viscosity measurement was performed by the cone-and-plate rheometer Stability studies In vitro skin permeation through Franz diffusion cells Drug deposition study was conducted using tape stripping to remove the stratum corneum followed by HPLC analysis of drug content Cell viability testing and protection against oxidative stress on mouse embryonic fi broblasts (3 T3) using MTT assay were evaluated In vivo antinfl ammatory effect was evaluated in female CD-1 mice through edema and myeloperoxidase inhibition Supplementary table I Continued SKIN-AGING AND INFLAMMAGING TREATMENT 349